Managing Potential Drug Interactions of Nirmatrelvir/Ritonavir in COVID-19 Patients: A Perspective from an Israeli Cross-Sector Collaboration

Shiri Guy-Alfandary; Sasha Zhurat; Maya Berlin; Tal De Haan; Itai Gueta; Renata Shihmanter; Ahuva Golik; Matitiahu Berkovitch; Sara Eyal; Lee H. Goldstein

doi:10.1002/cpt.2610

Managing Potential Drug Interactions of Nirmatrelvir/Ritonavir in COVID-19 Patients: A Perspective from an Israeli Cross-Sector Collaboration

Shiri Guy-Alfandary, Sasha Zhurat, Maya Berlin, Tal De Haan, Itai Gueta, Renata Shihmanter, Ahuva Golik, Matitiahu Berkovitch, Sara Eyal, Lee H. Goldstein^*

^*Corresponding author for this work

Clinical Departments

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	1156-1158
Number of pages	3
Journal	Clinical Pharmacology and Therapeutics
Volume	112
Issue number	6
DOIs	https://doi.org/10.1002/cpt.2610
State	Published - Dec 2022

Access to Document

10.1002/cpt.2610

Cite this

Guy-Alfandary, S., Zhurat, S., Berlin, M., De Haan, T., Gueta, I., Shihmanter, R., Golik, A., Berkovitch, M., Eyal, S., & Goldstein, L. H. (2022). Managing Potential Drug Interactions of Nirmatrelvir/Ritonavir in COVID-19 Patients: A Perspective from an Israeli Cross-Sector Collaboration. Clinical Pharmacology and Therapeutics, 112(6), 1156-1158. https://doi.org/10.1002/cpt.2610

@article{b7de4058ac51468b80d43f79b19479b4,

title = "Managing Potential Drug Interactions of Nirmatrelvir/Ritonavir in COVID-19 Patients: A Perspective from an Israeli Cross-Sector Collaboration",

author = "Shiri Guy-Alfandary and Sasha Zhurat and Maya Berlin and {De Haan}, Tal and Itai Gueta and Renata Shihmanter and Ahuva Golik and Matitiahu Berkovitch and Sara Eyal and Goldstein, {Lee H.}",

note = "Funding Information: This perspective received no funding. The authors acknowledge the helpful input of Mg. Hadas Rotem, M. Sc., and Dr. Einat Gorelik, Pharm.D., from the Israeli MOH.",

year = "2022",

month = dec,

doi = "10.1002/cpt.2610",

language = "אנגלית",

volume = "112",

pages = "1156--1158",

journal = "Clinical Pharmacology and Therapeutics",

issn = "0009-9236",

publisher = "Wiley-Blackwell",

number = "6",

}

Guy-Alfandary, S, Zhurat, S, Berlin, M, De Haan, T, Gueta, I, Shihmanter, R, Golik, A , Berkovitch, M, Eyal, S & Goldstein, LH 2022, 'Managing Potential Drug Interactions of Nirmatrelvir/Ritonavir in COVID-19 Patients: A Perspective from an Israeli Cross-Sector Collaboration', Clinical Pharmacology and Therapeutics, vol. 112, no. 6, pp. 1156-1158. https://doi.org/10.1002/cpt.2610

TY - JOUR

T1 - Managing Potential Drug Interactions of Nirmatrelvir/Ritonavir in COVID-19 Patients

T2 - A Perspective from an Israeli Cross-Sector Collaboration

AU - Guy-Alfandary, Shiri

AU - Zhurat, Sasha

AU - Berlin, Maya

AU - De Haan, Tal

AU - Gueta, Itai

AU - Shihmanter, Renata

AU - Golik, Ahuva

AU - Berkovitch, Matitiahu

AU - Eyal, Sara

AU - Goldstein, Lee H.

N1 - Funding Information: This perspective received no funding. The authors acknowledge the helpful input of Mg. Hadas Rotem, M. Sc., and Dr. Einat Gorelik, Pharm.D., from the Israeli MOH.

PY - 2022/12

Y1 - 2022/12

UR - http://www.scopus.com/inward/record.url?scp=85129879230&partnerID=8YFLogxK

U2 - 10.1002/cpt.2610

DO - 10.1002/cpt.2610

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 35521643

AN - SCOPUS:85129879230

SN - 0009-9236

VL - 112

SP - 1156

EP - 1158

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

IS - 6

ER -

Managing Potential Drug Interactions of Nirmatrelvir/Ritonavir in COVID-19 Patients: A Perspective from an Israeli Cross-Sector Collaboration

Access to Document

Other files and links

Cite this